NASDAQ:ALRN

Aileron Therapeutics - ALRN Stock Forecast, Price & News

$0.26

+0.01 (+4.00%)

(As of 10/7/2022 01:08 PM ET)

Add

Compare

Today's Range: $0.26
▼
$0.26
50-Day Range: $0.14
▼
$0.28
52-Week Range: $0.13
▼
$1.03

Volume: 700 shs
Average Volume: 1.66 million shs
Market Capitalization: $23.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $3.00

Aileron Therapeutics MarketRank™ Forecast

Analyst Rating: Hold
2.33 Rating Score
Upside/Downside: 1,053.8% Upside
$3.00 Price Target
Short Interest: Healthy
0.10% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($0.34) to ($0.26) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.05 out of 5 stars

Medical Sector

589th out of 1,075 stocks

Pharmaceutical Preparations Industry

272nd out of 537 stocks

3.2

Analyst's Opinion

Consensus Rating
Aileron Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 1 buy rating, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Aileron Therapeutics has a forecasted upside of 1,053.8% from its current price of $0.26.
Amount of Analyst Coverage
Aileron Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.10% of the float of Aileron Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Aileron Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Aileron Therapeutics has recently decreased by 25.79%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Aileron Therapeutics does not currently pay a dividend.
Dividend Growth
Aileron Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ALRN.

1.4

News and Social Media Coverage

News Sentiment
Aileron Therapeutics has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.41 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Aileron Therapeutics this week, compared to 0 articles on an average week.
Search Interest
9 people have searched for ALRN on MarketBeat in the last 30 days. This is an increase of 125% compared to the previous 30 days.
MarketBeat Follows
Only 1 people have added Aileron Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Aileron Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 3.50% of the stock of Aileron Therapeutics is held by insiders.
Percentage Held by Institutions
Only 35.33% of the stock of Aileron Therapeutics is held by institutions.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Aileron Therapeutics are expected to grow in the coming year, from ($0.34) to ($0.26) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Aileron Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Aileron Therapeutics is -0.79, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Aileron Therapeutics has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Aileron Therapeutics (NASDAQ:ALRN) Stock

Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. It has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Boston, Massachusetts.

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Stock News Headlines

October 1, 2022 | americanbankingnews.com

Aileron Therapeutics, Inc. (NASDAQ:ALRN) Short Interest Update

September 30, 2022 | finance.yahoo.com

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

September 22, 2022 | finance.yahoo.com

Aileron Therapeutics to Present and Participate in a Fireside Chat at the Ladenburg Thalmann 2022 Healthcare Conference

September 6, 2022 | finance.yahoo.com

Aileron Therapeutics to Present at the H.C. Wainwright 24th Annual Global Investment Conference

August 16, 2022 | finance.yahoo.com

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 16, 2022 | finance.yahoo.com

Aileron Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

August 1, 2022 | seekingalpha.com

Aileron slips 12% after announcing changes to breast cancer trial design

August 1, 2022 | finance.yahoo.com

Aileron Therapeutics Is Pleased to Outline Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

July 5, 2022 | benzinga.com

Aileron Therapeutics (NASDAQ:ALRN), Short Interest Report

July 5, 2022 | benzinga.com

Aileron Therapeutics (NASDAQ:ALRN), Analyst Ratings, Price Targets, Predictions

July 1, 2022 | marketwatch.com

Aileron Therapeutics Shares Down After Lung Cancer Data

June 29, 2022 | tmcnet.com

Aileron Therapeutics Announces Interim Data from Phase 1b

June 29, 2022 | finance.yahoo.com

Aileron Shares Fall After Early Data From Chemoprotective Agent In Lung Cancer Setting

June 29, 2022 | seekingalpha.com

Aileron drug fails to beat placebo in reducing chemo toxicities in lung cancer patients in trial

June 29, 2022 | finance.yahoo.com

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN-6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

May 19, 2022 | seekingalpha.com

Aileron begins dosing in phase 1b trial of ALRN-6924 to prevent toxicities due to chemotherapy

May 19, 2022 | finance.yahoo.com

Aileron Therapeutics Announces First Patients Treated in Phase 1b Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

May 17, 2022 | finance.yahoo.com

Aileron Therapeutics to Present at the H.C. Wainwright Global Investment Conference

May 13, 2022 | finance.yahoo.com

Aileron Therapeutics to Host Virtual KOL Investor Event on May 19, 2022

May 11, 2022 | finance.yahoo.com

Will Aileron Therapeutics (NASDAQ:ALRN) Spend Its Cash Wisely?

May 10, 2022 | finance.yahoo.com

Aileron Therapeutics Announces Late-Breaking Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at Upcoming Society for Investigative Dermatology 2022 Annual Meeting

May 6, 2022 | seekingalpha.com

Aileron Therapeutics GAAP EPS of -$0.09 misses by $0.01

May 5, 2022 | finance.yahoo.com

Aileron Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights

April 21, 2022 | finance.yahoo.com

Is Aileron Therapeutics (ALRN) Outperforming Other Medical Stocks This Year?

April 21, 2022 | nz.finance.yahoo.com

Aileron Expands Management Team with Appointment of Christopher Zergebel As Vice President, Program Management and Clinical Operations

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive ALRN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aileron Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

ALRN Company Calendar

Last Earnings: 8/15/2022
Today: 10/07/2022
Next Earnings (Estimated): 11/11/2022
Fiscal Year End: 12/31/2022

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ALRN
CUSIP: N/A
CIK: 1420565
Web: www.aileronrx.com
Phone: (617) 995-0900
Fax: N/A
Employees: 9
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $3.00
High Stock Price Forecast: $5.00
Low Stock Price Forecast: $1.00
Forecasted Upside/Downside: +1,053.8%
Consensus Rating: Hold
Rating Score (0-4): 2.33
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.33)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-26,160,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -75.39%
Return on Assets: -67.50%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 6.51
Quick Ratio: 6.51

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.48 per share
Price / Book: 0.54

Miscellaneous

Outstanding Shares: 90,820,000
Free Float: 87,645,000
Market Cap: $23.61 million
Optionable: Not Optionable
Beta: 2.04

Key Executives

Dr. Manuel C. Aivado M.D. (Age 52)
Ph.D., Pres, CEO & Director
Comp: $912.38k

Ms. Susan L. Drexler CPA (Age 52)
M.B.A., Interim CFO, Principal Financial Officer & Principal Accounting Officer

Dr. D. Allen Annis Ph.D. (Age 49)
Sr. VP of Research

Key Competitors

View All Competitors

Insiders & Institutions

Renaissance Technologies LLC
Bought 56,691 shares on 8/13/2022
Ownership: 0.127%

View All Insider Transactions
View All Institutional Transactions

ALRN Stock - Frequently Asked Questions

Should I buy or sell Aileron Therapeutics stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aileron Therapeutics in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ALRN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALRN, but not buy additional shares or sell existing shares.
View ALRN analyst ratings or view top-rated stocks.
What is Aileron Therapeutics' stock price forecast for 2022?: 3 equities research analysts have issued 12-month target prices for Aileron Therapeutics' stock. Their ALRN share price forecasts range from $1.00 to $5.00. On average, they predict the company's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,100.0% from the stock's current price.
View analysts price targets for ALRN or view top-rated stocks among Wall Street analysts.
How have ALRN shares performed in 2022?: Aileron Therapeutics' stock was trading at $0.5629 at the beginning of the year. Since then, ALRN stock has decreased by 55.6% and is now trading at $0.25.
View the best growth stocks for 2022 here.
When is Aileron Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Friday, November 11th 2022.
View our ALRN earnings forecast.
How were Aileron Therapeutics' earnings last quarter?: Aileron Therapeutics, Inc. (NASDAQ:ALRN) posted its quarterly earnings data on Monday, August, 15th. The company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09).

What other stocks do shareholders of Aileron Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Aileron Therapeutics investors own include Portola Pharmaceuticals (PTLA), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Allena Pharmaceuticals (ALNA), OPKO Health (OPK), Amarin (AMRN), Aldeyra Therapeutics (ALDX), Lexicon Pharmaceuticals (LXRX) and Nabriva Therapeutics (NBRV).
When did Aileron Therapeutics IPO?: (ALRN) raised $61 million in an initial public offering on Thursday, June 29th 2017. The company issued 3,800,000 shares at $15.00-$17.00 per share. BofA Merrill Lynch and Jefferies acted as the underwriters for the IPO and William Blair and Canaccord Genuity were co-managers.
What is Aileron Therapeutics' stock symbol?: Aileron Therapeutics trades on the NASDAQ under the ticker symbol "ALRN."
How do I buy shares of Aileron Therapeutics?: Shares of ALRN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Aileron Therapeutics' stock price today?: One share of ALRN stock can currently be purchased for approximately $0.25.
How much money does Aileron Therapeutics make?: Aileron Therapeutics (NASDAQ:ALRN) has a market capitalization of $22.71 million. The company earns $-26,160,000.00 in net income (profit) each year or ($0.33) on an earnings per share basis.
How can I contact Aileron Therapeutics?: Aileron Therapeutics' mailing address is 490 Arsenal Way, Watertown MA, 02472. The official website for the company is www.aileronrx.com. The company can be reached via phone at (617) 995-0900 or via email at hans@lifesciadvisors.com.

This page (NASDAQ:ALRN) was last updated on 10/7/2022 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Aileron Therapeutics - ALRN Stock Forecast, Price & News

Aileron Therapeutics MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows